About 2 results found for searched term "Ladiratuzumab" (0.124 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M24755 | Ladiratuzumab | Others |
| hLIV22 | ||
| Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer. | ||
| M24756 | Ladiratuzumab vedotin | Drug-Linker Conjugates for ADC |
| SGN-LIV1A | ||
| Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
